DB 006
Alternative Names: DB-006Latest Information Update: 04 Nov 2024
Price :
$50 *
At a glance
- Originator Derm-Biome Pharmaceuticals
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Skin cancer
Most Recent Events
- 29 Aug 2024 Preclinical trials in Skin cancer in Canada (Topical) prior to August 2024 (DermBiome Pharmaceuticals website; August 2024)